Ticker

VANCOUVER, BC, April 27th, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV OTCQB:BVAXF FRA:5LB0) today announced the acceptance of an abstract related to the PESCO study, an investigator-initiated, open-label, non-randomized phase 1B/2 trial to evaluate the safety and efficacy of combination of BioVaxys' MVP-S with pembrolizumab (Keytruda™) and cyclophosphamide in patients with recurrent epithelial ovarian…

VANCOUVER, BC, March 17, 2026 – TheNewswire  - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“ BioVaxys ” or the “ Company ”) is providing this bi-weekly update on the status of the management cease trade order granted on March 3, 2026 (the “ MCTO ”), by its principal regulator, the British Columbia Securities Commission (the “ BCSC ”) under National Policy 12-203 – Management Cease Trade Orders…

VANCOUVER, BC, March 31, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB0) (OTCQB: BVAXF) (“ BioVaxys ” or the “ Company ”) is providing this bi-weekly update on the status of the management cease trade order granted on March 3, 2026 (the “ MCTO ”), by its principal regulator, the British Columbia Securities Commission (the “ BCSC ”) under National Policy 12-203 – Management Cease Trade Orders…

VANCOUVER, BC, March 17, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“ BioVaxys ” or the “ Company ”) is providing this bi-weekly update on the status of the management cease trade order granted on March 3, 2026 (the “ MCTO ”), by its principal regulator, the British Columbia Securities Commission (the “ BCSC ”) under National Policy 12-203 – Management Cease Trade Orders (“…